Biocompatible Zn-Phthalocyanine/Gelatin Nanofiber Membrane for Antibacterial Therapy.

In this study, the fabrication and characterization of Zn-phthalocyanine/gelatin nanofibrous membranes is reported using the electrospinning technique. The membranes exhibit a homogeneous distribution of Zn-phthalocyanine within the gelatin matrix, maintaining the structural integrity and photosensitizing properties of the phthalocyanine. Scanning electron microscopy revealed that the electrospun fibers possess diameters ranging results as 100-300, 200-700, and 300-800 nm for Gel, ZnPc/Gel 1, and ZnPc/Gel 2, respectively.

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diabetes receiving maintenance dialysis with high-sensitivity C-reactive protein (hs-CRP) ≥ 2 mg l at baseline were randomized to receive clazakizumab (2.

Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.

CSL112 (apolipoprotein A-I [apoA-I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed to compare the pharmacokinetics (PKs), pharmacodynamics (PDs), and safety of CSL112 in Japanese and White subjects. A total of 34 Japanese subjects were randomized to receive a single infusion of CSL112 (2, 4, or 6 g) or placebo and 18 White subjects were randomized to receive a single dose of 6 g CSL112 or placebo, followed by PK/PD assessment and adverse events monitoring.